ByteDance's Quiet AI Bet: Anew Labs Raises $290M to Chase Isomorphic Labs

For all the noise about China's AI giants, the most consequential race in the sector may be happening in laboratories, not chatbots. This week, a Shanghai company that most people outside biotech have never heard of raised US$290 million — and its pedigree tells you why the money moved so fast.

Anew Labs, an AI drug discovery firm spun out of ByteDance, closed the round at a US$1.5 billion valuation, according to a source familiar with the deal. The investor list reads like a who's who of Chinese venture capital: HSG, the firm formerly known as Sequoia China, alongside IDG Capital and 5Y Capital. ByteDance itself retains a 56 per cent stake, meaning the TikTok parent is not merely an incubator but the controlling shareholder of a company now valued in unicorn territory.

To understand why this matters, you have to understand what Anew Labs actually builds. The company develops AI models for biomolecular structure prediction and design — the computational backbone of modern drug discovery. Its in-house foundation model, AnewFold, sits alongside Protenix, an open-source reproduction of AlphaFold 3, the protein-structure system from Google DeepMind and its Isomorphic Labs spin-off. In plain terms, Anew is trying to build a Chinese challenger to the most advanced molecular AI in the West. That ambition, not the funding headline, is the real story.

The local context is crucial for anyone watching Asia's capital flows. ByteDance has spent years diversifying beyond consumer internet, and healthcare is a natural adjacency: it is data-rich, computationally intensive, and politically favoured in Beijing. Anew Labs is not a random start-up that happened to attract ByteDance money — it is a strategic asset, kept majority-owned while external VCs buy in at a steep valuation. HSG's involvement is equally telling. The firm's rebrand from Sequoia China was a response to geopolitical pressures on US-linked capital; backing a domestic AI drug developer is exactly the kind of move that keeps it relevant in a market where Western LPs have grown cautious.

What does this signal about wealth and capital in Asia? Three things. First, AI drug discovery is becoming a distinct fundraising category in China, not a subplot of general AI enthusiasm. Investors are rushing to back domestic challengers to Anthropic and Isomorphic Labs, and they are doing so at scale — hundreds of millions, not seed rounds. Second, the strategic logic has shifted from software margins to scientific moats. Structure prediction models take years and enormous compute to train; the winners will be those with both capital and patience. Third, ByteDance's controlling stake complicates the usual venture narrative. This is not a founder-led garage story. It is a corporate spin-off with a tech giant's balance sheet behind it, which changes both the risk profile and the exit path.

The forward view is less about this single round than about the pipeline it implies. If Anew Labs can translate structure prediction into actual drug candidates, it will not just be a Chinese success story — it will be a competitive threat to the Western incumbents that currently define the field. For investors watching Asia, the question is no longer whether China can build frontier AI in life sciences. It is whether the capital now flowing into companies like Anew will produce molecules that reach patients, and returns that justify the valuations. The money has arrived. The science is the next test.